安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Technology Melior Pharmaceuticals | Melior Affiliate
Melior Pharmaceuticals leverages the proprietary technology if its affiliate company, Melior Discovery, to identify new indications for drugs that have existing clinical data in other indications Melior Discovery is a pioneer of in vivo phenotypic screening and a leader in the area of drug repositioning
- About Melior Pharmaceuticals | Clinical Stage Diabetes, NASH, Parkinson . . .
Melior Pharmaceuticals is a mid-stage biopharmaceutical company developing a pipeline of de-risked therapies in areas with significant unmet needs Our lead clinical stage candidates are in the areas of diabetes, NASH, Parkinson’s Disease and sleep disorders
- Management Team - Melior Pharmaceuticals
Meet the management team of Melior Pharmaceuticals, responsible for business development and investment inquiries
- MELIOR PHARMACEUTICALS ANNOUNCES EXECUTION OF LICENSE AGREEMENT FOR . . .
July 29, 2021 Exton, PA – Melior Pharmaceuticals (Melior) announced that it completed a definitive licensing agreement with Adhera Therapeutics, Inc (OTCPK: ATRX; Adhera) for Melior’s Parkinson’s disease (PD) candidate, MLR-1019 (armesocarb) As with all of Melior’s drug candidates, MLR-1019 is a repositioned drug that has demonstrated
- Melior Pharmaceuticals | Biopharmaceutical Research Development . . .
Melior Pharmaceuticals is a mid-stage biopharmaceutical company developing a pipeline of innovative, de-risked drug candidates in disease areas with significant unmet needs
- Contact Melior Pharmaceuticals | Biopharma, Clinical Stage Business . . .
Contact Melior Pharmaceuticals office in Exton, Pennsylvania for business development inquiries regarding clinical stage biopharma therapies
- Mesocarb - Melior Pharmaceuticals
Melior is now developing mesocarb in Parkinson’s disease levodopa induced dyskinesia, given compelling preclinical data in animal models of PD-LID: o Reduces levodopa induced dyskinesia in parkonsonian rats o Highly targeted approach; strong in vivo affinity and selectivity for DAT o Enhances anti-parkionsonian activity of levodopa activity
- News Press Releases - Melior Pharmaceuticals
Melior Pharmaceuticals Announces Entry Into "Letter-of-Intent" for the Acquisition of Armescarb by Adhera Therapeutics June 7, 2021 READ MORE DOWNLOAD PDF
|
|
|